Royalty Pharma Plc Cl A (RPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Sales | 2,354,554 | 2,237,215 | 2,289,463 | 2,122,353 | 1,814,254 |
| Gross Profit | 2,354,554 | 2,237,215 | 2,289,463 | 2,122,353 | 1,814,254 |
| Operating Expenses | 862,404 | 1,930,150 | 858,748 | 526,954 | -808,922 |
| Operating Income | 1,492,150 | 307,065 | 1,430,715 | 1,595,399 | 2,623,176 |
| Interest Expense | 187,187 | 187,961 | 166,142 | 157,059 | 268,573 |
| Other Income | 395,125 | 110,960 | -23,372 | 263,614 | 106,816 |
| Pre-tax Income | 1,700,088 | 230,064 | 1,241,201 | 1,701,954 | 2,461,419 |
| Net Income Continuous | 1,700,088 | 230,064 | 1,241,201 | 1,701,954 | 2,461,419 |
| Minority Interests | 565,254 | 187,232 | 621,473 | 726,914 | 112,884 |
| Net Income | $1,134,834 | $42,832 | $619,728 | $975,040 | $2,348,535 |
| EPS Basic Total Ops | 2.54 | 0.10 | 1.49 | 1.32 | 1.32 |
| EPS Basic Continuous Ops | 3.80 | 0.53 | 2.99 | 4.53 | 6.56 |
| EPS Diluted Total Ops | 2.53 | 0.10 | 1.49 | 1.32 | 1.32 |
| EPS Diluted Continuous Ops | 2.82 | 0.53 | 2.99 | 4.53 | 6.56 |
| EPS Diluted Before Non-Recurring Items | 4.49 | 3.68 | 2.91 | 1.61 | N/A |
| EBITDA(a) | $1,512,649 | $334,091 | $1,473,873 | $1,630,172 | $2,659,890 |